Even after steroids scandals in Major League Baseball and more than 30 athletes were withheld from the winter Olympics in Vancouver for breaking anti-doping rules, why do athletes still engage in pharmacological cheating? The latest concern among sport officials is a new erythropoietin called Hematide, still in investigate trials. Dr. Gary Wadler, chairman of the World Anti-Doping Agency's Prohibited List and Methods Sub-Committee, talks to host Bruce Japsen about the never-ending battle against the abuse of pharmacology in order to enhance athletic ability.
The Battle Continues Against Pharmacological Cheating in Sports
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Even after steroids scandals in Major League Baseball and more than 30 athletes were withheld from the winter Olympics in Vancouver for breaking anti-doping rules, why do athletes still engage in pharmacological cheating? The latest concern among sport officials is a new erythropoietin called Hematide, still in investigate trials. Dr. Gary Wadler, chairman of the World Anti-Doping Agency's Prohibited List and Methods Sub-Committee, talks to host Bruce Japsen about the never-ending battle against the abuse of pharmacology in order to enhance athletic ability.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
<p>FCS and SHTG: Are We Meeting the Need?</p>
CME/CE
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
0.50 credits
<p>IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
Clinician's Roundtable
AI and Hair Loss: Measuring Progress with Data-Driven Insights
<p>AI and Hair Loss: Measuring Progress with Data-Driven Insights</p>
Cardiology
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
<p>Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF</p>
Cardiology
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
<p>Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial </p>
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
<p>Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial</p>
Cardiology
NYHA FC and Finerenone Response: Clinical Trial Insights
<p><span data-contrast="auto" xml:lang="EN-US">NYHA FC and Finerenone Response: Clinical Trial Insights</span><span data-ccp-props='{"134245417":false,"335559739":0}'> </span></p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?